| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/20/2002 | CA2066313C New pharmaceutical composition |
| 08/20/2002 | CA2063886C Polyethylene protein conjugates |
| 08/20/2002 | CA2062653C Promotion of wound-healing with 15-keto-prostaglandin compounds |
| 08/20/2002 | CA2058144C Process for the production of threo-4-alkoxy-5-(arylhydroxymethyl)-2(5h)-furanones |
| 08/20/2002 | CA2056364C Compositions and methods of effecting contraception |
| 08/20/2002 | CA2052041C Benzimidazole derivatives, their preparation and use |
| 08/20/2002 | CA2045077C Anti-epileptics |
| 08/20/2002 | CA2020199C Uses of sulphated sugars |
| 08/20/2002 | CA2020171C Gastroprotective pharmaceutical preparations containing n-benzyl-n-((1s,5s)-6,6-dimethylbicyclo[3,1,1]-hept-2-ylethoxy-ethyl)-morpholinium salts |
| 08/19/2002 | CA2372606A1 Compound containing vitamin c prepared during application, use of enzymes to form vitamin c for topical use and cosmetic treatment procedure |
| 08/15/2002 | WO2002063308A2 Prediction of wound healing by urinary nitrate assay |
| 08/15/2002 | WO2002063014A2 Human tyrosine-specific protein phosphatase |
| 08/15/2002 | WO2002062963A2 Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same |
| 08/15/2002 | WO2002062840A1 INTERFERON-α INDUCED GENE |
| 08/15/2002 | WO2002062824A2 Method of treating amyloid ? precursor disorder |
| 08/15/2002 | WO2002062810A2 Linkable sialyl lewis x analogs |
| 08/15/2002 | WO2002062804A1 Oxazolyl-pyrazole derivatives as kinase inhibitors |
| 08/15/2002 | WO2002062799A1 Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents |
| 08/15/2002 | WO2002062798A2 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose |
| 08/15/2002 | WO2002062795A2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof |
| 08/15/2002 | WO2002062794A2 Compounds |
| 08/15/2002 | WO2002062793A1 Thiazole compounds as tgf-beta inhibitors |
| 08/15/2002 | WO2002062789A1 Pyrazole compounds useful as protein kinase inhibitors |
| 08/15/2002 | WO2002062788A1 Sulfonamide compounds, their preparation and use |
| 08/15/2002 | WO2002062787A1 Pyrazoles as tgf inhibitors |
| 08/15/2002 | WO2002062786A1 Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1h-benzimidazoles |
| 08/15/2002 | WO2002062784A1 Piperidinee derivatives as neurokinin 1 antagonists |
| 08/15/2002 | WO2002062780A2 Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands |
| 08/15/2002 | WO2002062778A2 Anti-thrombotic compounds, production and use thereof as medicaments |
| 08/15/2002 | WO2002062777A2 Amino ceramide-like compounds and therapeutic methods of use |
| 08/15/2002 | WO2002062776A1 2-amino-4-(pyridin-2-yl)-thiazole derivatives as transforming growth factor beta (tgf-beta) inhibitors |
| 08/15/2002 | WO2002062775A1 2-acylaminothiazole derivative or its salt |
| 08/15/2002 | WO2002062774A1 Thiazole derivatives for treating ppar related disorders |
| 08/15/2002 | WO2002062773A1 Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors |
| 08/15/2002 | WO2002062766A2 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 08/15/2002 | WO2002062762A2 Potassium channel openers |
| 08/15/2002 | WO2002062761A1 Aminal diones as potassium channel openers |
| 08/15/2002 | WO2002062753A1 Thiazolamines and their use as tgf-beta inhibitors |
| 08/15/2002 | WO2002062751A1 Novel cystine derivatives and inhibitors for the activation of inflammatory factors |
| 08/15/2002 | WO2002062750A1 Cannabinoid receptor ligands |
| 08/15/2002 | WO2002062748A1 Carboxylic amides, the production and use thereof as medicaments |
| 08/15/2002 | WO2002062745A1 Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity |
| 08/15/2002 | WO2002062423A1 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| 08/15/2002 | WO2002062422A1 Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof |
| 08/15/2002 | WO2002062398A2 Radioactively labelled conjugates of phosphonates |
| 08/15/2002 | WO2002062392A2 Water-soluble compositions of bioactive lipophilic compounds |
| 08/15/2002 | WO2002062391A2 Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea |
| 08/15/2002 | WO2002062390A1 Medicinal compositions for treating lower uropathy |
| 08/15/2002 | WO2002062389A1 Remedies for urinary diseases comprising lpa receptor controlling agents |
| 08/15/2002 | WO2002062387A1 Treatment of conditions with a need of gsk-3 inhibition |
| 08/15/2002 | WO2002062386A2 Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration |
| 08/15/2002 | WO2002062369A2 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
| 08/15/2002 | WO2002062357A1 Methods and devices for tissue repair |
| 08/15/2002 | WO2002062353A1 Composition containing sucrafate and a topical anesthetic for human and animals and method of use thereof |
| 08/15/2002 | WO2002062351A1 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
| 08/15/2002 | WO2002062350A1 Methods for the administration of amifostine and related compounds |
| 08/15/2002 | WO2002062349A1 Method and composition for inhibiting the incidence and proliferation of nervous system and brain cancer cells |
| 08/15/2002 | WO2002062348A1 Eugenol, optionally in combination with 2-methoxyestradiol, as a cancer chemopreventative agent |
| 08/15/2002 | WO2002062347A1 Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis |
| 08/15/2002 | WO2002062346A1 Method of treating substance abuse with quetiapine |
| 08/15/2002 | WO2002062345A1 Use of galantamine for accelerating transport of intraluminal content |
| 08/15/2002 | WO2002062343A2 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS |
| 08/15/2002 | WO2002062342A1 A method for the treatment of heart failure |
| 08/15/2002 | WO2002062341A1 Method and composition for the control of hair growth |
| 08/15/2002 | WO2002062340A1 Highly lipophilic camptothecin prodrugs, methods of preparation, and formulations thereof |
| 08/15/2002 | WO2002062339A1 Antibacterial compounds |
| 08/15/2002 | WO2002062338A1 Parenteral formulation containing epothilone analogs |
| 08/15/2002 | WO2002062337A1 Thiazolidinediones |
| 08/15/2002 | WO2002062336A1 Antifungal remedy formulation for external application |
| 08/15/2002 | WO2002062335A2 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
| 08/15/2002 | WO2002062334A2 Cancer chemopreventative compounds and compositions and methods of treating cancers |
| 08/15/2002 | WO2002062332A1 Pharmaceutical composition for treating multiple sclerosis |
| 08/15/2002 | WO2002062331A1 Cyanoacrylate compositions for prophylactic or therapeutic treatment of diseases manifesting themselves in and/or damaging cutaneous tissue |
| 08/15/2002 | WO2002062330A2 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs |
| 08/15/2002 | WO2002062329A1 Therapeutical and nutritional compositions containing pyruvic acid amd glutamine, having antioxidizing activity and capable of controlling overweight |
| 08/15/2002 | WO2002062328A1 New use |
| 08/15/2002 | WO2002062327A2 Method of treating neurological disorders using acetone derivatives |
| 08/15/2002 | WO2002062326A1 Parasiticidal compositions and methods of use |
| 08/15/2002 | WO2002062325A2 Method of treating conditions related to platelet activity |
| 08/15/2002 | WO2002062324A2 A treatment of oesophageal motility disorders and gastro-oesophageal reflux disease |
| 08/15/2002 | WO2002062323A2 Use of mglur5 antagonists for the treatment of pruritic conditions |
| 08/15/2002 | WO2002062322A2 Glycine betaine and its use as anti-hemorrhagic agent |
| 08/15/2002 | WO2002062321A2 Method for producing a floating tablet containing an active principle |
| 08/15/2002 | WO2002062320A1 Methods and compositions for reducing the taste of pharmaceutically active agents |
| 08/15/2002 | WO2002062318A2 Oral itraconazole formulations and methods of making the same |
| 08/15/2002 | WO2002062317A2 Bimodal dry powder formulation for inhalation |
| 08/15/2002 | WO2002062315A1 Rapid-onset medicament for the treatment of sexual dysfunction |
| 08/15/2002 | WO2002062310A1 Multifunctional particulate additive for personal care and cosmetic compositions, and the process of making the same |
| 08/15/2002 | WO2002062306A1 Nos inhibitors for treatment of wrinkles |
| 08/15/2002 | WO2002062302A2 Steroidal derivatives |
| 08/15/2002 | WO2002062301A2 Method and composition for rejuvinating cells, tissues, organs, hair and nails |
| 08/15/2002 | WO2002062300A2 Cholesterol-lowering agents as treatment for psychological and cognitive disorders |
| 08/15/2002 | WO2002062299A2 Improved controlled release oral dosage form |
| 08/15/2002 | WO2002062295A2 Pyridine-substituted benzanilides as potassium ion channel openers |
| 08/15/2002 | WO2002062293A2 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof |
| 08/15/2002 | WO2002062290A2 Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
| 08/15/2002 | WO2002062287A1 Process and container with low oxygen content and further containing mas |
| 08/15/2002 | WO2002062260A2 Improved ophthalmic and contact lens solutions containing forms of vitamin b |
| 08/15/2002 | WO2002055071A8 Compositions and methods for regulating lipoproteins and hypercholesterolmia with limonoids flavonoids and tocotrienols |
| 08/15/2002 | WO2002047685A3 Nmda receptor agonist pharmaceutical compositions |